Want to see HK:6618 full AI Analyst Report?
6618 Stock Chart & Stats
HK$36.74
HK$0.78(2.11%)
At close: 4:00 PM EDT
HK$36.74
HK$0.78(2.11%)
Day’s Range― - ―
52-Week RangeHK$31.84 - HK$71.70
Previous CloseN/A
Volume4.55M
Average Volume (3M)8.77M
Market Cap
HK$114.98B
Enterprise ValueHK$49.29K
Total Cash (Recent Filing)HK$47.41B
Total Debt (Recent Filing)HK$874.69M
Price to Earnings (P/E)16.0
Beta1.26
Next Earnings
Mar 29, 2027EPS Estimate
1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.92
Shares Outstanding3,190,481,000
10 Day Avg. Volume8,370,343
30 Day Avg. Volume8,773,169
Financial Highlights & Ratios
PEG Ratio1.09
Price to Book (P/B)2.65
Price to Sales (P/S)2.17
P/FCF Ratio16.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$65.33Price Target Upside77.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.87
Revenue Forecast (FY)HK$85.71B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And DiversificationHealthy product growth alongside a meaningful service contribution indicates multiple avenues for expansion rather than reliance on one revenue stream. Continued top-line progress can strengthen platform scale, improve operating leverage, and support broader customer and partner adoption over the next several quarters.
Sustained Margin ExpansionNine consecutive quarters of year-over-year margin improvement provide evidence that profitability gains are becoming more durable. Higher operating income growing faster than revenue suggests scale benefits and execution are improving earnings quality, creating greater capacity to fund investment while pursuing long-term margin goals.
Conservative Balance Sheet And LiquidityExtremely low leverage and substantial liquidity give JD Health flexibility to invest, manage operating volatility, and support strategic initiatives without depending heavily on borrowing. The conservative balance sheet also strengthens resilience if category conditions weaken or investment requirements rise.
Bears Say
Free Cash Flow ResetThe move to zero free cash flow weakens near-term financial flexibility even though operating cash generation remains strong. If investment or working-capital needs stay elevated, less internally generated cash will be available for expansion, buybacks, or absorbing unexpected operating pressure.
Regulatory And Counterfeit HeadwindsRegulatory scrutiny and counterfeit-brand issues can disrupt category growth and require stronger compliance and execution before demand normalizes. Although management views regulation as favorable to compliant players over time, the transition may weigh on sales momentum and operating performance across supplements.
AI Monetization Remains UnprovenStrong user adoption has not yet translated into a proven independent revenue stream, leaving the economic return on AI investment uncertain. The company may need sustained spending and product development before monetization scales, which could delay returns and limit the near-term contribution to earnings.
JD Health International, Inc. News
6618 FAQ
What was JD Health International, Inc.’s price range in the past 12 months?
JD Health International, Inc. lowest stock price was HK$31.84 and its highest was HK$71.70 in the past 12 months.
What is JD Health International, Inc.’s market cap?
JD Health International, Inc.’s market cap is HK$114.98B.
When is JD Health International, Inc.’s upcoming earnings report date?
JD Health International, Inc.’s upcoming earnings report date is Mar 29, 2027 which is in 178 days.
How were JD Health International, Inc.’s earnings last quarter?
JD Health International, Inc. released its earnings results on Aug 13, 2026. The company reported HK$1.252 earnings per share for the quarter, missing the consensus estimate of HK$1.369 by -HK$0.117.
Is JD Health International, Inc. overvalued?
According to Wall Street analysts JD Health International, Inc.’s price is currently Undervalued.
Does JD Health International, Inc. pay dividends?
JD Health International, Inc. does not currently pay dividends.
What is JD Health International, Inc.’s EPS estimate?
JD Health International, Inc.’s EPS estimate is 1.12.
How many shares outstanding does JD Health International, Inc. have?
JD Health International, Inc. has 3,190,481,000 shares outstanding.
What happened to JD Health International, Inc.’s price movement after its last earnings report?
JD Health International, Inc. reported an EPS of HK$1.252 in its last earnings report, missing expectations of HK$1.369. Following the earnings report the stock price went up 1.698%.
Which hedge fund is a major shareholder of JD Health International, Inc.?
Currently, no hedge funds are holding shares in HK:6618
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JD Health International, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
13.17%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
JD Health International, Inc.
JD Health International Inc., functioning as an investment holding entity, runs an expansive digital healthcare platform across the People's Republic of China. The company supplies a diverse range of pharmaceutical and wellness products, such as over-the-counter and prescription medications, medical devices, and health supplements. These goods are distributed through both direct sales and an extensive online retail pharmacy network. Beyond product offerings, its comprehensive service suite includes virtual medical consultations, patient referrals to hospitals and doctors, health screening programs, genetic testing, and beauty care services. Additionally, it develops intelligent healthcare and wellness management solutions, alongside providing technical support and advertising services. The platform also facilitates access to various medical provisions, including general health examinations, cosmetic medical procedures, vaccination bookings, dental treatments, and nucleic acid testing. Incorporated in 2018 and headquartered in Beijing, People's Republic of China, JD Health International Inc. is a subsidiary of JD Jiankang Limited.
6618 Stock 12 Month Forecast
Average Price Target
HK$65.33
▲(77.82% Upside)
Technical Analysis
Kindstar Globalgene Technology, Inc.
―
Jinxin Fertility Group Ltd.
―
C-MER Eye Care Holdings Limited
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―